The lncRNA H19 and its mature product, miR-675, increase AKT/mTOR signaling in gastric cancer through the lncRNA-H19/miR-675/RUNX1 axis [225, 226], whereas in gallbladder cancer, the same lncRNA can act as an endogenous competing RNA (ecRNA) by decoying miR-294-5p to increase AKT expression [227]. The gene discussed is MTOR; the disease is gastric cancer.